Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization

The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.

paper rip
Eisai and Bristol ended an ADC collaboration • Source: Shutterstock

Eisai Co., Ltd.’s partnership with Bristol Myers Squibb Company on the antibody-drug conjugate farletuzumab ecteribulin (FZEC) appears to be a casualty of Bristol’s R&D prioritization program. Eisai announced the end of the three-year partnership on FZEC, formerly known as MORAb-202, on 1 July and said it plans to accelerate development of the product and conduct development and commercialization independently.

Key Takeaways
  • Eisai plans to accelerate development of farletuzumab ecteribulin after regaining full rights from Bristol Myers Squibb.

Bristol paid handsomely for rights to co-develop and co-commercialize FZEC in regions including the US, Europe and Asia in 2021....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats

 

The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.

Replimune CRL Could Hold Warning For Accelerated Approvals

 

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By 

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.